Werner Hoellriegl

Title: Werner Hoellriegl – Innovator in Gene Therapy and Hemophilia Treatment

Introduction

Werner Hoellriegl is a notable inventor based in Altenmarkt/Triesting, Austria. With a focus on advancing medical treatments, he has made significant contributions to the field of gene therapy, particularly in relation to hemophilia A. His work not only reflects his ingenuity but also his commitment to improving patient outcomes through innovative solutions.

Latest Patents

Hoellriegl holds two patents that showcase his expertise in medical advancements. The first patent focuses on "Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression." This invention provides methods for expressing codon-altered polynucleotides in mammalian cells, potentially revolutionizing the treatment of hemophilia A. The second patent revolves around "Subcutaneous administration of ADAMTS13," which outlines methods for administering ADAMTS13 formulations to address conditions linked to ADAMTS13 and von Willebrand factor dysfunction. Notably, it highlights the unexpectedly high bioavailability of these formulations when administered subcutaneously.

Career Highlights

Throughout his career, Hoellriegl has been associated with Takeda Pharmaceutical Company Limited, a global leader in the pharmaceutical industry. His dedicated work has led to important advancements in therapeutic strategies for managing bleeding disorders, particularly hemophilia A.

Collaborations

Hoellriegl collaborates with talented professionals, including Hanspeter Rottensteiner and Alexandra Nathalie Kopic. Together, they are pushing the boundaries of medical innovation, focusing on improving treatments and patient care in their field.

Conclusion

Werner Hoellriegl stands out as a dedicated inventor whose work in gene therapy is paving the way for new treatment modalities for hemophilia A. With his extensive patent portfolio and collaborative spirit, he continues to impact the medical landscape positively, ultimately benefitting patients worldwide.